Status:
COMPLETED
Phase II Trial of Consolidative Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer
Lead Sponsor:
AHS Cancer Control Alberta
Collaborating Sponsors:
Cross Cancer Institute
Conditions:
Extensive Stage Small Cel Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The majority of patients with small cell lung cancer have incurable extensive stage disease. The usual initial treatment for this condition is chemotherapy which produces responses in about 50-80% of ...
Eligibility Criteria
Inclusion
- Histologic or cytologic confirmation of small cell lung cancer
- extensive stage disease
- adequate pulmonary function tests (FEV-1\>1.0, DLCO\>50%)
- patients of childbearing potential must practice adequate contraception
- age ≧ 18 years
- Karnofsky performance status ≧ 70
- documented objective response to initial chemotherapy
- signed study-specific informed consent form
Exclusion
- complete or subtotal tumor resection
- non-small cell histology
- prior or concurrent malignancy except non-melanoma skin cancer unless disease-free for at least 5 years
- prior chest or neck RT
- inadequate pulmonary function tests (FEV-1\<1.0 OR DLCO\<50%)
- pregnant
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00643396
Start Date
February 1 2008
End Date
January 1 2012
Last Update
February 26 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2